Press Releases
CEO of the Year | Samsung Biologics John Rim
John Rim has been named “CEO of the Year” by Korea’s economic magazine, Hankyung Business, for his leadership in achieving outstanding financial performance for Samsung Biologics in 2021.
Rim was credited for having delivered record-breaking revenues for two consecutive quarters in Q2 and Q3 of 2021. The market projects the company’s annual revenue and operating profit to increase 29% and 74% respectively.
Rim was also credited for engaging global clients and entering into numerous CDMO contracts for various therapeutics including COVID-19 treatments and mRNA vaccines, based on the company’s excellent capabilities and technologies.
Since he took over his new role in Samsung Biologics in December 2020, Rim has activitely optimized the company’s manufacturing processes to be able to respond to market demand more quickly. He continues to grow and diversify the company’s business portfolio through expansions including the building of the mRNA drug substance manufacturing suite, and the construction of the company’s fourth plant known as the ‘Super Plant’. Upon completion of the ‘Super Plant’ in 2023, Samsung Biologics will hold 620,000L of total manufacturing capacity, responsible for approximately a quarter of the entire global biopharmaceutical contract manufacturing capacity.
John Rim has been named “CEO of the Year” by Korea’s economic magazine, Hankyung Business, for his leadership in achieving outstanding financial performance for Samsung Biologics in 2021.
Rim was credited for having delivered record-breaking revenues for two consecutive quarters in Q2 and Q3 of 2021. The market projects the company’s annual revenue and operating profit to increase 29% and 74% respectively.
Rim was also credited for engaging global clients and entering into numerous CDMO contracts for various therapeutics including COVID-19 treatments and mRNA vaccines, based on the company’s excellent capabilities and technologies.
Since he took over his new role in Samsung Biologics in December 2020, Rim has activitely optimized the company’s manufacturing processes to be able to respond to market demand more quickly. He continues to grow and diversify the company’s business portfolio through expansions including the building of the mRNA drug substance manufacturing suite, and the construction of the company’s fourth plant known as the ‘Super Plant’. Upon completion of the ‘Super Plant’ in 2023, Samsung Biologics will hold 620,000L of total manufacturing capacity, responsible for approximately a quarter of the entire global biopharmaceutical contract manufacturing capacity.